1
|
Annex BH, Bristow MR, Frangogiannis NG, Kelly DP, Kontaridis M, Libby P, MacLellan WR, McNamara CA, Mann DL, Pitt GS, Sipido KR. JACC: Basic to Translational Science Top Reviewers 2023: With Appreciation and Gratitude. JACC Basic Transl Sci 2024; 9:161. [PMID: 38362353 PMCID: PMC10864951 DOI: 10.1016/j.jacbts.2023.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/17/2024]
Affiliation(s)
| | | | | | | | | | | | | | | | - Douglas L. Mann
- Address for correspondence: Dr Douglas L. Mann, Editor-in-Chief, JACC: Basic to Translational Science, American College of Cardiology, Heart House, 2400 N Street Northwest, Washington, DC 20037, USA.
| | | | | |
Collapse
|
2
|
Annex BH, Bristow MR, Frangogiannis NG, Kelly DP, Kontaridis M, Libby P, MacLellan WR, McNamara CA, Mann DL, Pitt GS, Sipido KR. JACC: Basic to Translational Science Top Reviewers 2022: With Appreciation and Gratitude. JACC Basic Transl Sci 2023; 8:236. [PMID: 36908670 PMCID: PMC9998454 DOI: 10.1016/j.jacbts.2023.01.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
|
3
|
Aistrup GL, Pfeiffer R, Goodrow R, Cordeiro J, Ercan-Sencicek AG, Desai M, Kontaridis M. Abstract P1089: Short-QT & Long-QT Associated Trpm4 Mutations. Circ Res 2022. [DOI: 10.1161/res.131.suppl_1.p1089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cardiac arrhythmias are responsible for 200-300 thousand deaths/year. Despite considerable research effort, much remains to be elucidated concerning the underlying mechanisms of arrhythmogenesis. Mutations in transient receptor potential melastatin 4 (TRPM4), a widely expressed Ca
2+
-activated nonselective cation channel, have been associated with causing cardiac arrhythmias. However, direct genotype-phenotype correlation of arrhythmogenic TRPM4 mutant variants are often complicated, as this channel is not primary to the cardiac action potential. Here, we assessed the electrophysiological and post-transcriptional molecular properties of a single mutation (R892C)-TRPM4 associated with short QT syndrome (SQTS) and a triple mutation (R250C|A432T|G582S)-TRPM4 associated with long QT syndrome (LQTS), using stably transfected HEK293 cells. Overall, protein expression of the triple mutant was found to be significantly reduced, with increased proteasomal degradation, but enhanced SUMOylation, as compared to either WT or the single R892 mutant TRPM4 channel. Consequently, expression of R250C|A432T|G582S-TRPM4 was significantly lower at the cellular membrane than either R892C- and WT-TRPM4. In contrast, while total expression of TRPM4 was not significantly different between WT and the R892C single mutant, although the R892C exhibited increase aggregation. Patch-clamp cellular electrophysiology experiments indicated that both single and triple TRPM4 mutant channels could be activated by lower Ca
2+
concentrations compared to WT. However, R892C-TRPM4 channels inactivated faster, while R250C|A432T|G582S-TRPM4 channels inactivated much slower compared to WT. These data as obtained in our homologous recombinant overexpression system reveal that while the R892C-TRPM4 mutant variant exhibited normal-to-higher levels of expression and increased Ca
2+
-activation sensitivity, its tendency to aggregate combined with faster inactivation can result in overall loss-of-function compared to WT, correlative with SQTS. Conversely, while the R250C|A432T|G582S-TRPM4 mutant variant exhibited reduced expression and perturbed trafficking, its increased Ca
2+
-activation sensitivity and slow inactivation can result in overall gain-of-function compared to WT, correlative with LQTS.
Collapse
|
4
|
Chen J, Ma Q, King JS, Sun Y, Xu B, Zhang X, Zohrabian S, Guo H, Cai W, Li G, Bruno I, Cooke JP, Wang C, Kontaridis M, Wang DZ, Luo H, Pu WT, Lin Z. aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model. Life Sci Alliance 2020; 3:e201900424. [PMID: 31843959 PMCID: PMC6918510 DOI: 10.26508/lsa.201900424] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Revised: 12/04/2019] [Accepted: 12/05/2019] [Indexed: 02/06/2023] Open
Abstract
Myocardial recovery from ischemia-reperfusion (IR) is shaped by the interaction of many signaling pathways and tissue repair processes, including the innate immune response. We and others previously showed that sustained expression of the transcriptional co-activator yes-associated protein (YAP) improves survival and myocardial outcome after myocardial infarction. Here, we asked whether transient YAP expression would improve myocardial outcome after IR injury. After IR, we transiently activated YAP in the myocardium with modified mRNA encoding a constitutively active form of YAP (aYAP modRNA). Histological studies 2 d after IR showed that aYAP modRNA reduced cardiomyocyte (CM) necrosis and neutrophil infiltration. 4 wk after IR, aYAP modRNA-treated mice had better heart function as well as reduced scar size and hypertrophic remodeling. In cultured neonatal and adult CMs, YAP attenuated H2O2- or LPS-induced CM necrosis. TLR signaling pathway components important for innate immune responses were suppressed by YAP/TEAD1. In summary, our findings demonstrate that aYAP modRNA treatment reduces CM necrosis, cardiac inflammation, and hypertrophic remodeling after IR stress.
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing/administration & dosage
- Adaptor Proteins, Signal Transducing/genetics
- Animals
- Animals, Newborn
- Apoptosis/drug effects
- Cardiomegaly/drug therapy
- Cardiomegaly/etiology
- Cell Survival/drug effects
- Cells, Cultured
- Disease Models, Animal
- Humans
- Injections, Intramuscular
- Mice
- Mice, Inbred C57BL
- Myocardial Reperfusion Injury/complications
- Myocarditis/drug therapy
- Myocarditis/etiology
- Myocardium/immunology
- Myocytes, Cardiac/metabolism
- Neutrophil Infiltration/drug effects
- RNA Editing
- RNA, Messenger/administration & dosage
- RNA, Messenger/genetics
- Transcription Factors/administration & dosage
- Transcription Factors/genetics
- YAP-Signaling Proteins
Collapse
Affiliation(s)
- Jinmiao Chen
- Boston Children's Hospital, Boston, MA, USA
- Department of Cardiovascular Surgery and Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Qing Ma
- Boston Children's Hospital, Boston, MA, USA
| | | | - Yan Sun
- Masonic Medical Research Institute, Utica, NY, USA
| | - Bing Xu
- Masonic Medical Research Institute, Utica, NY, USA
| | | | | | - Haipeng Guo
- Boston Children's Hospital, Boston, MA, USA
- Department of Critical Care Medicine, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan, China
| | - Wenqing Cai
- Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA, USA
| | - Gavin Li
- Boston Children's Hospital, Boston, MA, USA
| | - Ivone Bruno
- Houston Methodist Research Institute, Houston, TX, USA
| | - John P Cooke
- Houston Methodist Research Institute, Houston, TX, USA
| | - Chunsheng Wang
- Department of Cardiovascular Surgery and Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China
| | | | | | - Hongbo Luo
- Boston Children's Hospital, Boston, MA, USA
| | - William T Pu
- Boston Children's Hospital, Boston, MA, USA
- Harvard Stem Cell Institute, Cambridge, MA, USA
| | - Zhiqiang Lin
- Boston Children's Hospital, Boston, MA, USA
- Masonic Medical Research Institute, Utica, NY, USA
| |
Collapse
|
5
|
Kaikkonen LA, Sätzler V, Roy A, Contreras M, Xu B, Stroll S, McCarthy J, Molkentin JD, Das S, Kontaridis M. Abstract 252: Activated Fibroblast-specific Deletion of RhoA Reduces Cardiac Fibrosis Through Regulation of the Non-canonical p38-MAPK Signaling Pathway. Circ Res 2019. [DOI: 10.1161/res.125.suppl_1.252] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective:
Heart failure is a progressive disease characterized by cardiomyocyte (CM) loss, interstitial fibrosis, loss of ventricular compliance and chamber remodeling. Role of cardiac fibroblasts is implicated in the process, but specific molecular mechanisms regulating their function remain unclear. Previously, we showed that in mice, in response to stress, CM-specific deletion of RhoA, a Ras-related small G protein, accelerated cardiac dilation, with significant loss of contractile function, but it also significantly reduced cardiac fibrosis. Therefore, here, we focused on understanding the role of RhoA specifically in myofibroblast transformation and the fibrotic response.
Results:
We generated mice with activated fibroblast-specific deletion of RhoA using a tamoxifen (TMX) inducible periostin-cre promoter (RhoAfl/fl::PSTN Cre/+). 10-wk-old male RhoAfl/fl::PSTN Cre/+ or control mice were treated with angiotensin-phenylephrine (AngPE) or saline for 4 wk using osmotic minipumps and fed either with TMX or regular diet. Following TMX-AngPE treatment, the RhoAfl/fl::PSTN Cre/+ mice showed significantly decreased cardiac fibrosis, as compared to controls (0.9% vs. 3.2%, respectively). Moreover, while overall cardiac function following AngPE treatment was similar at 4 wk in all groups, hearts from the TMX-RhoAfl/fl::PSTN Cre/+ mice had significantly reduced septal thickness, as compared to controls. Expression of fetal genes, ANF, BNP, and β-MHC, as well as markers of fibrosis, including α-SMA and CTGF, were similarly induced in control and TMX-RhoAfl/fl::PSTN Cre/+ mice. However, TMX-RhoAfl/fl::PSTN Cre/+ mice had reduced expression of TGF-β1, thrombospondin-5 and Col1a2. Finally, RhoA deletion in activated fibroblasts did not affect the canonical TGFβ signaling pathway, as expected; instead, we found TMX-RhoAfl/fl::PSTN Cre/+ hearts had reduced non-canonical p38-MAPK signaling, suggestive of cellular-specific effects of RhoA regulation in the onset of cardiac disease and fibrosis.
Conclusions:
These data confirm the primacy of the RhoA pathway in the fibrotic response in vivo and identify potential novel downstream targets and possible therapeutic strategies for treatment of cardiac fibrosis and heart failure.
Collapse
Affiliation(s)
| | | | | | | | - Bing Xu
- Masonic Med Rsch Institute, Utica, NY
| | | | | | | | | | | |
Collapse
|
6
|
Jaffré F, Wang G, Roberts A, Pu W, Hahn A, Kontaridis M. Abstract 397: Generation of Raf1 Mutant and Crispr-cas9 Corrected Isogenic iPSC-derived Cardiomyocytes to Model Hypertrophic Cardiomyopathy in Noonan Syndrome. Circ Res 2015. [DOI: 10.1161/res.117.suppl_1.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Hypertrophic cardiomyopathy (HCM) is a major cause of death in infants and children. Noonan Syndrome (NS), an autosomal dominant RASopathy disorder, is characterized by multiple defects, including short stature, facial dysmorphia, and congenital heart defects that include HCM. RASopathies are caused by germ-line mutations that affect the canonical RAS-MAPK pathway. Indeed, 95% of NS patients with a mutation in
Raf1
, a gene that plays an integral role in this signaling cascade, exhibit HCM. However, the molecular mechanisms that elicit HCM in these patients remain poorly understood.
Objective:
To generate human NS
Raf1
induced-pluripotent stem cells (iPSCs), correct the mutation by genome editing and subsequently differentiate isogenic iPSC lines into cardiomyocytes to characterize the molecular and genetic basis of HCM in NS patients.
Results:
We generated iPSCs from skin fibroblasts obtained from a NS pediatric patient with a single point mutation in the
Raf1
gene. Using electroporation of four episomal vectors containing the Yamanaka factors, we obtained several iPSC clones with normal karyotypes and strong expression of pluripotent markers (Nanog, Oct4, Lin28, Sox2) as detected by RT-qPCR and immunofluorescence. We next corrected the mutation in the NS
Raf1
iPSCs using genome editing CRISPR-Cas9 nickase technology. Correction of the
Raf1
mutation was determined at the clonal level by PCR followed by Restriction Fragment Length Polymorphism and confirmed by Sanger sequencing. In addition, by inducing a Cas9 nickase-dependent frame shift mutation we also generated an isogenic iPSC line where
Raf1
gene was knockout (KO), as demonstrated at the RNA level by RT-qPCR and at the protein level by Western Blot. We next differentiated these multiple iPSC lines (mutant, corrected and KO) into isogenic beating cardiomyocytes, with more >98% of the cells positive for specific cardiomyocyte markers (α-actinin and cardiac TroponinT).
Conclusion:
We have successfully generated human NS
Raf1
isogenic iPSC lines and corresponding cardiomyocytes. Currently, we are in progress of characterizing these cardiac cells to determine the molecular basis of NS-dependent HCM. Ultimately, our work should reveal new targets to treat HCM in NS patients.
Collapse
|
7
|
Korf B, Ahmadian R, Allanson J, Aoki Y, Bakker A, Wright EB, Denger B, Elgersma Y, Gelb BD, Gripp KW, Kerr B, Kontaridis M, Lazaro C, Linardic C, Lozano R, MacRae CA, Messiaen L, Mulero-Navarro S, Neel B, Plotkin S, Rauen KA, Roberts A, Silva AJ, Sittampalam SG, Zhang C, Schoyer L. The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach. Am J Med Genet A 2015; 167A:1741-6. [PMID: 25900621 DOI: 10.1002/ajmg.a.37089] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Accepted: 03/15/2015] [Indexed: 12/15/2022]
Abstract
"The Third International Meeting on Genetic Disorders in the RAS/MAPK Pathway: Towards a Therapeutic Approach" was held at the Renaissance Orlando at SeaWorld Hotel (August 2-4, 2013). Seventy-one physicians and scientists attended the meeting, and parallel meetings were held by patient advocacy groups (CFC International, Costello Syndrome Family Network, NF Network and Noonan Syndrome Foundation). Parent and patient advocates opened the meeting with a panel discussion to set the stage regarding their hopes and expectations for therapeutic advances. In keeping with the theme on therapeutic development, the sessions followed a progression from description of the phenotype and definition of therapeutic endpoints, to definition of genomic changes, to identification of therapeutic targets in the RAS/MAPK pathway, to preclinical drug development and testing, to clinical trials. These proceedings will review the major points of discussion.
Collapse
Affiliation(s)
- Bruce Korf
- University of Alabama at Birmingham, Alabama
| | | | - Judith Allanson
- (Retired) Children's Hospital of Eastern Ontario, Ottawa, Canada
| | - Yoko Aoki
- Tohoku University School of Medicine, Sendai, Japan
| | | | - Emma Burkitt Wright
- Manchester Centre for Genomic Medicine, UK.,Manchester Academic Health Science Center, Manchester, UK
| | - Brian Denger
- Parent Project Muscular Dystrophy, Hackensack, New Jersey
| | | | - Bruce D Gelb
- Icahn School of Medicine at Mount Sinai, New York
| | - Karen W Gripp
- A.I. duPont Hospital for Children, Wilmington, Delaware
| | - Bronwyn Kerr
- Manchester Centre for Genomic Medicine, Manchester, UK
| | - Maria Kontaridis
- Harvard Medical School and Beth Israel Deaconess Medical Cancer Center, Boston, Massachusetts
| | - Conxi Lazaro
- Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | | | | | - Calum A MacRae
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | | | | | - Benjamin Neel
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Scott Plotkin
- Massachusetts General Hospital, Boston, Massachusetts
| | - Katherine A Rauen
- University of California, Davis MIND Institute, Sacramento, California
| | - Amy Roberts
- Boston Children's Hospital, Massachusetts.,Harvard Medical School, Massachusetts
| | | | - Sitta G Sittampalam
- National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Maryland
| | | | | |
Collapse
|